MD
MDCXW
Medicus Pharma Ltd.
$0.6795
0.00%
$27.6M
No data for this timeframe.
Vol
Market Cap$27.6M
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$1.6K
SEC Reports4
Recent Activity
May 27, 2026
SEC
Medicus Pharma entered into a $22M secured note financing with Streeterville Capital, with $12M received upfront and $10
8-K — Impact 8/10
Apr 29, 2026
SEC
Medicus Pharma Ltd. filed Amendment No. 1 to its 2025 Form 10-K solely to add Part III information (directors, executive
10-K/A — Impact 2/10
Apr 24, 2026
SEC
Medicus Pharma received a Nasdaq delisting notice for failing to maintain a $1.00 minimum bid price and simultaneously a
8-K — Impact 8/10
Latest Reports
BEARISH
8-K
8/10
Medicus Pharma entered into a $22M secured note financing with Streeterville Capital, with $12M received upfront and $10
May 27, 2026
NEUTRAL
10-K/A
2/10
Medicus Pharma Ltd. filed Amendment No. 1 to its 2025 Form 10-K solely to add Part III information (directors, executive
Apr 29, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| UBS Group AG | $1.6K | — |
1 institutional holders with $1.6K total value (2,299 shares) as of 2025-Q1. Top holders: UBS.
Top Institutional Holders — 2025-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 2,299 | $1.6K | 100.0% | — |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 0 mixed, 1 neutral. Avg impact: 6.3/10.
BEARISH
8-K
8/10
Medicus Pharma entered into a $22M secured note financing with Streeterville Capital, with $12M rece
May 27, 2026
NEUTRAL
10-K/A
2/10
Medicus Pharma Ltd. filed Amendment No. 1 to its 2025 Form 10-K solely to add Part III information (
Apr 29, 2026
BEARISH
8-K
8/10
Medicus Pharma received a Nasdaq delisting notice for failing to maintain a $1.00 minimum bid price
Apr 24, 2026
BEARISH
EFFECT
7/10
Medicus Pharma Ltd. has three registration statements (S-1 and two S-3s) that have become effective,
Mar 30, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.